Literature DB >> 21939411

Risk and predictive factors of hypoalbuminemia in cancer patients following extensive abdominal surgery despite total parenteral nutritional support.

Elena Critselis1, Demosthenes B Panagiotakos, Anastasios Machairas, Antonis Zampelas, Anthony N Critselis, Evangelos Polychronopoulos.   

Abstract

Postoperative hypoalbuminemia is associated with adverse outcomes, particularly in cancer patients. The risk and predictors of hypoalbuminemia in cancer patients following extensive abdominal surgery (EAS), despite total parenteral nutrition (TPN) support, were evaluated. A prospective cohort study (n = 115) was conducted in patients with gastrointestinal and/or urogenital malignancies following extensive (n = 81) or moderate (n = 34) abdominal surgery (mean age ± standard deviation: 66.0 ± 11.7 years). EAS patients received daily TPN, including 200 mL of 5% human albumin solution. Serum albumin (SA) levels and hypoalbuminemia (SA < 3.5 g/dL) were assessed daily. EAS patients had an elevated risk of hypoalbuminemia during the first postoperative week [relative risk (RR): 3.12; 95% confidence interval (95% CI): 1.64-5.91]. Postoperative hypoalbuminemia was associated with surgery duration (RR: 1.76; 95% CI: 1.32-2.36), preoperative SA (RR: 0.24; 95% CI: 0.11-0.55), blood (RR: 1.46; 95% CI: 1.04-2.04) and Ringer's lactated solution (RR: 1.52; 95% CI: 1.12-2.07) volumes transfused intra-operatively. Therefore, despite TPN, cancer patients who underwent EAS had an elevated risk of postoperative hypoalbuminemia. Additional tailored nutritional support among this group is necessary to deter adverse clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21939411     DOI: 10.3109/09637486.2011.618825

Source DB:  PubMed          Journal:  Int J Food Sci Nutr        ISSN: 0963-7486            Impact factor:   3.833


  1 in total

1.  Early post-operative serum albumin level predicts survival after curative nephrectomy for kidney cancer: a retrospective study.

Authors:  Yongquan Tang; Zhihong Liu; Jiayu Liang; Ruochen Zhang; Kan Wu; Zijun Zou; Chuan Zhou; Fuxun Zhang; Yiping Lu
Journal:  BMC Urol       Date:  2018-12-06       Impact factor: 2.264

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.